An observational study in Hypothalamic Amenorrhea, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.
Among the 43 studies in Amenorrhea with a site in United States, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 13 observational ones, and was the 36th registered.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
Browse Amenorrhea studies →7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
University of Virginia · Sites in United States
Ages 14–30 · Women only
Massachusetts General Hospital · Sites in United States
Ages 14–30 · Women only
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
University of Colorado, Colorado Springs · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 1989; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 85 across 26 observational studies indexed under Amenorrhea.
Median enrollment 37 across the 30 interventional studies, 111 across the 13 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 1 study filed under Amenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Amenorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00589654Memorial Sloan Kettering Cancer CenterMenstrual Cycle Maintenance and Quality of Life: A Prospective Study | 2026-12 |
| NCT05629377Mayo ClinicHypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH) | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Amenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypothalamic amenorrhea (HA) occurs during reproductive years and results in stopped menstrual cycles and infertility which can be prolonged from months to years and is characterized by varying combinations of psychosocial stress, anxiety, high levels of physical activity, and/or weight loss. Data from our group indicates that one-third of women with HA (mean age: 27 yrs) have preclinical cardiovascular disease (CVD) measured noninvasively as vascular dysfunction and vascular inflammation. This study will use HA as a marker of fertility status for cardiovascular health and perform dense-phenotyping using remote patient monitoring (FitBit) and patient reported outcomes (questionnaires) to determine which HA phenotypes are related to preclinical CVD and inflammation.
Premenopausal women with hypothalamic amenorrhea at Mayo Clinic Florida.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypothalamic Amenorrhea (HA) duration
Duration of HA by month of amenorrhea (absence of menstruation)
Time frame: 3 months
Vascular dysfunction
Measured by reactive hyperemic index (RHI)
Time frame: 3 months
Psychosocial stress
Measured by NIH PROMIS® short-form questionnaires
Time frame: 3 months
Perceived stress
Measured by the validate perceived stress scale questionnaire, a 10-item questionnaire, scores range from 0 to 40; higher scores indicate higher levels of perceived stress.
Time frame: 3 months
Step count
Measured by Fitbit Versa 2 watch that tracks steps per day, active and resting heart rate, sleep hours per day
Time frame: 3 months
Physical activity level
Measured by Fitbit Versa 2 watch that tracks amount of light physical activity, moderate, and vigorous activity
Time frame: 3 months
Heart Rate
Measured by Fitbit Versa 2 watch that tracks heart rate
Time frame: 3 months
Caloric intake and nutrition
Measured using a self-reported food diary
Time frame: 3 days
Vascular inflammation
concentration of cytokines multiplex immunoassay platform
Time frame: 3 months
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.